Insider Intelligence delivers leading-edge research to clients in a variety of forms, including full-length reports and data visualizations to equip you with actionable takeaways for better business decisions.
In-depth analysis, benchmarks and shorter spotlights on digital trends.
Learn More
Interactive projections with 10k+ metrics on market trends, & consumer behavior.
Learn More
Proprietary data and over 3,000 third-party sources about the most important topics.
Learn More
Industry KPIs
Industry benchmarks for the most important KPIs in digital marketing, advertising, retail and ecommerce.
Learn More
Client-only email newsletters with analysis and takeaways from the daily news.
Learn More
Analyst Access Program
Exclusive time with the thought leaders who craft our research.
Learn More

About Insider Intelligence

Our goal at Insider Intelligence is to unlock digital opportunities for our clients with the world’s most trusted forecasts, analysis, and benchmarks. Spanning five core coverage areas and dozens of industries, our research on digital transformation is exhaustive.
Our Story
Learn more about our mission and how Insider Intelligence came to be.
Learn More
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Contact Us
Speak to a member of our team to learn more about Insider Intelligence.
Contact Us
See our latest press releases, news articles or download our press kit.
Learn More
Advertising & Sponsorship Opportunities
Reach an engaged audience of decision-makers.
Learn More
Browse our upcoming and past events, recent podcasts, and other featured resources.
Learn More
Tune in to eMarketer's daily, weekly, and monthly podcasts.
Learn More

Teladoc Health turns out a steep $3.1B loss in Q2—how much finger-pointing goes to Livongo?

The news: Teladoc Health announced a steep loss of $3.1 billion in Q2.

  • Teladoc posted a net loss of $3.1 billion or $19.22 per share for Q2 2022 compared with $133.8 million or $0.86 per share in Q2 2021.
  • Teladoc reported a $3 billion non-cash goodwill impairment charge for Q2 2022 and close to $10 billion in impairment charges for the first half of 2022.

Putting the numbers in context: Teladoc’s impairment charge is likely a result of its acquisition of digital therapeutics company Livongo in 2020.

  • Teladoc bought Livongo to consolidate an app that offers primary care, chronic care, and telehealth, per Fierce Healthcare. However, Teladoc may have overpaid in its $13.9 billion Livongo acquisition.
  • As the US GDP shrank for the second consecutive quarter, sparking recession fears, Teladoc CEO Jason Gorevic acknowledged “increased uncertainty in the macroeconomic backdrop” affecting the company’s earnings.

For context, Teladoc also posted a loss in Q1 2022.

The silver lining: Teladoc showed progress for its Primary360 business, which the company says recently added new clients and capabilities.

  • In addition, Teladoc’s overall revenues increased 18% to $592.4 million from $503.1 million in the second quarter of 2021.
  • And Teladoc expects positive results from its Chronic Care Complete business, which launched in February.

Teladoc has also received industry praise for its robust telehealth capabilities. And although telehealth has experienced a drop-off after the beginning of the COVID-19 pandemic, we expect the number of telehealth users to grow to 116.6 million in 2025 versus 99.2 million in 2022, according to our Telehealth Users forecast.

What’s next? Teladoc expects results for the rest of 2022 to be on the lower end of its outlook. The company projects a fiscal year 2022 outlook range of $2.4 billion to $2.5 billion.